Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

592 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pregnancy-associated breast cancer: evaluating maternal and foetal outcomes. A national study.
Prior L, O'Dwyer R, Farooq AR, Greally M, Ward C, O'Leary C, Aslam R, Darwish W, Ahmed N, Othman EC, Watson G, Kelly D, Gleeson J, Kiely L, Hassan A, Walsh EM, O'Reilly D, Jones A, Featherstone H, Lim M, Murray H, Hennessy BT, Smyth LM, Leonard G, Grogan L, Breathnach O, Calvert P, Horgan AM, Coate L, Jordan EJ, O'Mahony D, Gupta R, Keane MM, Westrup J, Duffy K, O'Connor M, Morris PG, Kennedy MJ, O'Reilly S, McCaffrey J, Kelly CM, Carney D, Gullo G, Crown J, Higgins MJ, Walsh PM, Walshe JM. Prior L, et al. Among authors: leonard g. Breast Cancer Res Treat. 2021 Aug;189(1):269-283. doi: 10.1007/s10549-021-06263-y. Epub 2021 Jun 14. Breast Cancer Res Treat. 2021. PMID: 34125341
Hepatic arterial infusion: a treatment at the "end of an era"?
Power DG, Leonard GD. Power DG, et al. Among authors: leonard gd. J Clin Oncol. 2008 May 20;26(15):2597-8; author reply 2598-9. doi: 10.1200/JCO.2008.16.8385. J Clin Oncol. 2008. PMID: 18487579 No abstract available.
Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 trial.
Gullo G, J Eustace A, Canonici A, M Collins D, Kennedy MJ, Grogan L, Breathhnach O, McCaffrey J, Keane M, Martin MJ, Gupta R, Leonard G, O'Connor M, Calvert PM, Donnellan P, Walshe J, McDermott E, Scott K, Hernando A, Parker I, W Murray D, C O'Farrell A, Maratha A, Dicker P, Rafferty M, Murphy V, O'Donovan N, M Gallagher W, Ky B, Tryfonopoulos D, Moulton B, T Byrne A, Crown J. Gullo G, et al. Among authors: leonard g. Ther Adv Med Oncol. 2019 Jul 24;11:1758835919864236. doi: 10.1177/1758835919864236. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31384312 Free PMC article.
Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.
Sanoff HK, Goldberg RM, Ivanova A, O'Reilly S, Kasbari SS, Kim RD, McDermott R, Moore DT, Zamboni W, Grogan W, Cohn AL, Bekaii-Saab TS, Leonard G, Ryan T, Olowokure OO, Fernando NH, McCaffrey J, El-Rayes BF, Horgan AM, Sherrill GB, Yacoub GH, O'Neil BH. Sanoff HK, et al. Among authors: leonard g. Cancer. 2018 Aug 1;124(15):3118-3126. doi: 10.1002/cncr.31552. Epub 2018 Jun 15. Cancer. 2018. PMID: 29905927 Free article. Clinical Trial.
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lièvre A, Uronis H, Elimova E, Grootscholten C, Geboes K, Zafar S, Snow S, Ko AH, Feeney K, Schenker M, Kocon P, Zhang J, Zhu L, Lei M, Singh P, Kondo K, Cleary JM, Moehler M; CheckMate 577 Investigators. Kelly RJ, et al. N Engl J Med. 2021 Apr 1;384(13):1191-1203. doi: 10.1056/NEJMoa2032125. N Engl J Med. 2021. PMID: 33789008 Clinical Trial.
Optimal therapy for oesophageal cancer.
Leonard GD, McCaffrey JA, Maher M. Leonard GD, et al. Cancer Treat Rev. 2003 Aug;29(4):275-82. doi: 10.1016/s0305-7372(02)00131-7. Cancer Treat Rev. 2003. PMID: 12927567 Review.
592 results